MedTrace Logo

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

NCT01214759 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2016-02-08

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.

Conditions

Interventions

DRUG

Truvada

Tenofovir 200mg/emtricitabine 300mg once a day

DRUG

Raltegravir

Raltegravir 400mg twice a day

Sponsors & Collaborators

Principal Investigators

  • Karen J Vigil, MD · The University of Texas Health Science Center, Houston

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-12-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01214759 on ClinicalTrials.gov